Raloxifene Hydrochloride
Overview
Raloxifene Hydrochloride is a selective estrogen receptor modulator (SERM) used primarily for the prevention and treatment of osteoporosis in postmenopausal women. In addition, it is used to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and those at high risk for invasive breast cancer.
API suppliers (8)
Suppliers of Raloxifene Hydrochloride evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 6 of 8 suppliers.
4 of 8 hold a GMP certificate on record in the EU or UK registers
- TAPI NL BVNetherlands1 active DMF
- OLON SPAItaly1 active DMF GMP on record
- ERREGIERRE SPAItaly1 active DMF GMP on record
- CAMBREX PROFARMACO MILANO SRLItaly1 active DMF GMP on record
- GLOCHEM INDUSTRIES PRIVATE LTD1 active DMF
- EXCELLA GMBH GMP on record
- Cipla USA, Inc.USA
- Sichuan Xieli Pharmaceutical Co LtdChina
EU CEP holders (9)
Companies holding a valid EU Certificate of Suitability (CEP) for Raloxifene Hydrochloride, from the EDQM certification database. A CEP holder is a documented EU-market source of the substance — not necessarily the manufacturer — and these are not yet profiled in our directory.
Therapeutic areas
Do you supply Raloxifene Hydrochloride? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.